sarepta therapeutics inc. - SRPT
SRPT
Close Chg Chg %
22.13 1.10 4.97%
Closed Market
23.23
+1.10 (4.97%)
Volume: 3.16M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: sarepta therapeutics inc. - SRPT
SRPT Key Data
| Open $21.93 | Day Range 21.62 - 23.29 |
| 52 Week Range 10.42 - 64.80 | Market Cap $2.44B |
| Shares Outstanding 104.99M | Public Float 99.44M |
| Beta 0.28 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$8.32 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.42M |
SRPT Performance
| 1 Week | 16.32% | ||
| 1 Month | 39.02% | ||
| 3 Months | 9.01% | ||
| 1 Year | -57.32% | ||
| 5 Years | -69.52% |
SRPT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About sarepta therapeutics inc. - SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT At a Glance
Sarepta Therapeutics, Inc.
215 First Street
Cambridge, Massachusetts 02142
| Phone | 1-617-274-4000 | Revenue | 2.20B | |
| Industry | Pharmaceuticals: Major | Net Income | -713,410,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 15.576% | |
| Fiscal Year-end | 12 / 2026 | Employees | 835 | |
| View SEC Filings |
SRPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.98 |
| Price to Book Ratio | 1.98 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.762 |
| Enterprise Value to Sales | 1.026 |
| Total Debt to Enterprise Value | 0.461 |
SRPT Efficiency
| Revenue/Employee | 2,632,619.162 |
| Income Per Employee | -854,383.234 |
| Receivables Turnover | 4.231 |
| Total Asset Turnover | 0.601 |
SRPT Liquidity
| Current Ratio | 2.317 |
| Quick Ratio | 1.482 |
| Cash Ratio | 0.858 |
SRPT Profitability
| Gross Margin | 59.78 |
| Operating Margin | -29.923 |
| Pretax Margin | -31.945 |
| Net Margin | -32.454 |
| Return on Assets | -19.511 |
| Return on Equity | -53.472 |
| Return on Total Capital | -32.723 |
| Return on Invested Capital | -28.387 |
SRPT Capital Structure
| Total Debt to Total Equity | 91.139 |
| Total Debt to Total Capital | 47.682 |
| Total Debt to Total Assets | 31.034 |
| Long-Term Debt to Equity | 90.157 |
| Long-Term Debt to Total Capital | 47.168 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Sarepta Therapeutics Inc. - SRPT
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 933.01M | 1.24B | 1.90B | 2.20B | |
Sales Growth
| +32.93% | +33.26% | +52.97% | +15.58% | |
Cost of Goods Sold (COGS) incl D&A
| 181.85M | 194.74M | 356.82M | 884.13M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 54.60M | 58.89M | 53.89M | 58.47M | |
Depreciation
| 53.88M | 56.99M | 51.19M | 55.47M | |
Amortization of Intangibles
| 714.00K | 1.90M | 2.70M | 3.00M | |
COGS Growth
| +34.64% | +7.09% | +83.23% | +147.78% | |
Gross Income
| 751.16M | 1.05B | 1.55B | 1.31B | |
Gross Income Growth
| +32.52% | +39.60% | +47.35% | -14.95% | |
Gross Profit Margin
| +80.51% | +84.34% | +81.24% | +59.78% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.28B | 1.32B | 1.33B | 1.97B | |
Research & Development
| 839.38M | 844.38M | 778.47M | 1.49B | |
Other SG&A
| 441.98M | 472.04M | 548.60M | 478.94M | |
SGA Growth
| +26.11% | +2.74% | +0.81% | +48.59% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 127.32M | 418.85M | 7.84M | 25.15M | |
EBIT after Unusual Expense
| (657.52M) | (686.67M) | 210.24M | (682.92M) | |
Non Operating Income/Expense
| 20.80M | 188.59M | 68.92M | 18.83M | |
Non-Operating Interest Income
| 27.72M | 85.97M | 71.77M | 36.69M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 53.25M | 22.01M | 18.39M | 38.14M | |
Interest Expense Growth
| -16.18% | -58.67% | -16.44% | +107.38% | |
Gross Interest Expense
| 53.25M | 22.01M | 18.39M | 38.14M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (689.96M) | (520.10M) | 260.77M | (702.23M) | |
Pretax Income Growth
| -64.69% | +24.62% | +150.14% | -369.28% | |
Pretax Margin
| -73.95% | -41.83% | +13.71% | -31.94% | |
Income Tax
| 13.53M | 15.88M | 25.54M | 11.19M | |
Income Tax - Current - Domestic
| 13.19M | 15.29M | 24.81M | 10.17M | |
Income Tax - Current - Foreign
| 944.00K | 753.00K | 972.00K | 1.38M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| (612.00K) | (165.00K) | (249.00K) | (363.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (703.49M) | (535.98M) | 235.24M | (713.41M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (703.49M) | (535.98M) | 235.24M | (713.41M) | |
Net Income Growth
| -67.99% | +23.81% | +143.89% | -403.27% | |
Net Margin Growth
| -75.40% | -43.11% | +12.37% | -32.45% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (703.49M) | (535.98M) | 235.24M | (713.41M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (703.49M) | (535.98M) | 235.24M | (713.41M) | |
EPS (Basic)
| -8.0344 | -5.8007 | 2.4742 | -7.1256 | |
EPS (Basic) Growth
| -55.90% | +27.80% | +142.65% | -388.00% | |
Basic Shares Outstanding
| 87.56M | 92.40M | 95.08M | 100.12M | |
EPS (Diluted)
| -8.0344 | -5.8007 | 2.3382 | -7.1256 | |
EPS (Diluted) Growth
| -55.90% | +27.80% | +140.31% | -404.75% | |
Diluted Shares Outstanding
| 87.56M | 92.40M | 107.88M | 100.12M | |
EBITDA
| (475.60M) | (208.93M) | 271.97M | (599.30M) | |
EBITDA Growth
| -18.94% | +56.07% | +230.17% | -320.35% | |
EBITDA Margin
| -50.97% | -16.80% | +14.30% | -27.26% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 22.522 | |
| Number of Ratings | 27 | Current Quarters Estimate | 0.663 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 3.042 | |
| Last Quarter’s Earnings | 0.765 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -7.13 | Next Fiscal Year Estimate | 1.356 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 20 | 24 | 21 |
| Mean Estimate | 0.66 | 0.44 | 3.04 | 1.36 |
| High Estimates | 3.28 | 1.29 | 4.49 | 5.19 |
| Low Estimate | -0.18 | -0.28 | 0.18 | -2.95 |
| Coefficient of Variance | 120.00 | 92.02 | 35.37 | 124.93 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 13 | 12 | 14 |
| UNDERWEIGHT | 3 | 3 | 2 |
| SELL | 3 | 3 | 3 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Sarepta Therapeutics Inc. - SRPT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Sarepta Therapeutics Inc. - SRPT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 5, 2026 | Cristin L. Rothfuss EVP, General Counsel | 139,348 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 2,257,437.60 |
| Mar 5, 2026 | Ian M. Estepan Chief Operating Officer | 208,875 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Ian M. Estepan Chief Operating Officer | 205,574 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 3,330,298.80 |
| Mar 5, 2026 | Ian M. Estepan Chief Operating Officer | 204,699 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 3,316,123.80 |
| Mar 5, 2026 | Ian M. Estepan Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Louise Rodino-Klapac President, R&D and Tech Ops | 232,155 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Louise Rodino-Klapac President, R&D and Tech Ops | 228,437 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 3,700,679.40 |
| Mar 5, 2026 | Louise Rodino-Klapac President, R&D and Tech Ops | 227,670 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 3,688,254.00 |
| Mar 5, 2026 | Louise Rodino-Klapac President, R&D and Tech Ops | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Ryan Wong Chief Financial Officer | 135,595 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.2 per share | 2,196,639.00 |